Skip to content
October 19, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Patient Advocacy and Support
  • Global Landmarks to Glow in Teal, Green, and Pink for National Metastatic Breast Cancer Awareness Day
  • Patient Advocacy and Support

Global Landmarks to Glow in Teal, Green, and Pink for National Metastatic Breast Cancer Awareness Day

Ali Ikhwan October 19, 2026 8 minutes read
global-landmarks-to-glow-in-teal-green-and-pink-for-national-metastatic-breast-cancer-awareness-day

NEW YORK, NY — As the world enters the second week of October, a month traditionally synonymous with pink ribbons and messages of early detection, a global movement is preparing to shift the spotlight toward a more sobering reality. On October 13, 2026, National Metastatic Breast Cancer Awareness Day, more than 325 landmarks across the globe will be illuminated in teal, green, and pink. This coordinated display is part of the #LightUpMBC campaign, an initiative spearheaded by METAvivor Research and Support to raise awareness and critical funding for Stage 4 breast cancer—the only form of the disease that is currently terminal.

Main Facts: A Global Beacon for the "Forgotten" Stage

Metastatic Breast Cancer (MBC), also referred to as Stage 4, occurs when breast cancer spreads beyond the initial site to vital organs such as the bones, liver, lungs, or brain. Despite the ubiquity of breast cancer awareness campaigns, the MBC community often feels marginalized by narratives that focus exclusively on "winning the battle" or "finishing treatment." For those with MBC, treatment never ends; it is a lifelong process of managing a terminal illness.

The #LightUpMBC campaign seeks to rectify this by turning awareness into tangible action. On the evening of October 13, 195 cities across all 50 U.S. states and 20 countries will participate in a synchronized lighting event. From One World Trade Center in New York City to the Mactan-Cebu Airport in the Philippines, these landmarks will shed their traditional colors to adopt the MBC tri-color palette:

  • Teal: Representing healing and spirituality.
  • Green: Symbolizing the triumph of spring over winter, renewal, and hope.
  • Pink: Acknowledging the origins of the disease.

The centerpiece of the day’s activities is "#LightUpMBC Live," a virtual broadcast scheduled for 8 p.m. ET / 5 p.m. PT. The program, which will stream for free on YouTube, Facebook Live, and LiveOne, aims to bridge the gap between patient experience and scientific progress. It will feature a mix of patient testimonials, insights from leading oncology researchers, and performances by world-class entertainers, including Tony Award winners and nominees.

Chronology: From a Single Bridge to a Global Phenomenon

The origins of #LightUpMBC are rooted in a personal story of friendship and loss. The campaign was inspired by Jessica Moore, a young woman who was diagnosed with metastatic breast cancer and passed away in 2017 at the age of 36. Before her death, Moore expressed a simple wish: to see a local landmark lit up in the MBC awareness colors to help people understand that her disease was different from the "curable" stages of breast cancer.

Her best friend, Laura Inahara, took up the mantle, founding #LightUpMBC to honor Moore’s legacy. The timeline of the movement’s growth reflects a rapidly increasing demand for MBC-specific advocacy:

  • 2017: The inaugural lighting took place at the Memorial Bridge in Portsmouth, New Hampshire. It was the first landmark in the world to be illuminated specifically for metastatic breast cancer.
  • 2018–2020: The campaign gained traction across New England and eventually the East Coast, as more patients and families petitioned their local governments to participate.
  • 2021: Despite the challenges of the global pandemic, the campaign transitioned into a digital-heavy format, launching the first "LightUpMBC Live" stream to connect a homebound community.
  • 2022–2025: The movement went truly global, securing participation from major international sites like Niagara Falls and the Ness Bridge in Scotland.
  • 2026: The campaign reaches its current record-breaking scale, with over 325 landmarks and more than $2.7 million raised for research to date.

What began as a localized tribute has evolved into a sophisticated international operation, utilizing social media and digital broadcasting to ensure that even those who cannot physically visit a landmark can participate in the "Sea of Light."

Supporting Data: The Stark Reality of Stage 4

The necessity of the #LightUpMBC campaign is underscored by sobering statistics provided by the National Cancer Institute and the American Cancer Society. While survival rates for early-stage breast cancer have improved significantly over the last three decades, the statistics for metastatic disease remain a challenge.

Mortality and Diagnosis

In 2026, an estimated 42,670 people in the United States alone are expected to die from breast cancer. This averages out to approximately 117 deaths every single day. It is a common misconception that metastatic disease only occurs in patients who "neglected" their health or failed to get mammograms. In reality:

  • Nearly 6% of new breast cancer diagnoses are "de novo" metastatic, meaning the cancer has already spread by the time it is first detected.
  • For the remaining majority, MBC can return months, years, or even decades after a patient has been declared "cancer-free" or completed their initial rounds of surgery, chemotherapy, and radiation.

The Funding Gap

One of the primary drivers behind METAvivor’s mission is the disparity in research funding. Historically, only 2% to 5% of all breast cancer research funding has been dedicated to metastatic disease. The vast majority of resources are funneled into prevention and early detection. While these are vital components of public health, they do little to help the hundreds of thousands of people currently living with Stage 4 disease.

METAvivor remains the only U.S. organization that dedicated 100% of its net proceeds—including every dollar raised through #LightUpMBC—to Stage 4 research. By focusing exclusively on the metastatic stage, the organization aims to identify why cancer spreads and how to stop it once it has reached other organs.

Official Responses: Voices from the Front Lines

The leadership of METAvivor and the creators of the campaign emphasize that while the lights are a beautiful tribute, the ultimate goal is survival.

Dr. Kelly Shanahan, a physician and the METAvivor Board President, provides a unique perspective as both a medical professional and a patient. Diagnosed with MBC in 2013, Shanahan has outlived many of the initial projections for her condition. "When I was diagnosed, I certainly didn’t think I’d still be here 13 years later," she stated. "My hope and the hope of so many others lies in research. #LightUpMBC is the biggest contributor to this research and is also a way to bring us together as a community."

Laura Inahara, the founder of the campaign, highlighted the emotional weight of the event. "Jessica Moore hoped to illuminate one local landmark. Today, her legacy helps families around the world shine a light for the people they love," Inahara said. She noted that the campaign does more than raise money; it teaches patients how to advocate for themselves in a healthcare system that often treats Stage 4 as a foregone conclusion.

The live event will be hosted by Tami Eagle Bowling, who has lived with MBC for 11 years, and Broadway star Kara Lindsay. Bowling, who also serves as the Campaign Director, emphasized the importance of the broadcast’s educational component. "We want people to meet the individuals behind the lights. This isn’t just a statistic; it’s mothers, daughters, sisters, and friends who are fighting for more time."

Implications: Shifting the Narrative from Awareness to Survival

The #LightUpMBC campaign represents a broader shift in the oncology landscape. For years, the "Pink Ribbon" movement focused on awareness as a means to an end—encouraging women to get mammograms. However, for the MBC community, awareness is not enough. The implication of this global movement is a demand for a "survivability" model.

Transforming the Disease

The ultimate goal of METAvivor-funded research is to transform metastatic breast cancer from a terminal diagnosis into a chronic, manageable condition—much like HIV/AIDS or diabetes. This requires a shift in how clinical trials are designed and how new therapies are approved. By funding projects that specifically target the mechanisms of metastasis, METAvivor is pushing the scientific community toward "precision medicine" that can adapt as the cancer evolves and becomes resistant to standard treatments.

Psychological and Social Impact

Beyond the scientific implications, #LightUpMBC has profound psychological effects on the patient community. The month of October can be a period of "pink fatigue" and isolation for MBC patients, as they are bombarded with "survivor" stories that do not reflect their reality. Seeing major landmarks like the Willis Tower or Niagara Falls lit in teal and green provides a powerful sense of validation. It signals to the world that their lives matter and that their specific struggle is being recognized on a global stage.

Call to Action

As the campaign approaches its 2026 iteration, the public is encouraged to participate not just by watching the livestream, but by actively engaging with the cause. Supporters are invited to photograph participating landmarks and share them on social media using the hashtags #LightUpMBC and #METAvivor. This "digital illumination" serves to amplify the message, ensuring that the 117 people lost every day to this disease are not forgotten, and that the quest for a cure for Stage 4 continues with renewed urgency.

For more information on participating landmarks, to view the livestream, or to make a donation toward life-saving research, visit www.lightupmbc.org.


About METAvivor: METAvivor Research and Support Inc. is a 501(c)(3) non-profit organization dedicated to the specific fight against metastatic breast cancer. Through a rigorous peer-review process that involves both scientific experts and patient advocates, the organization ensures that every dollar raised goes toward the most promising Stage 4 research projects. Since its inception, METAvivor has remained a leader in patient-led advocacy, working to ensure that quality of life and longevity are at the forefront of the cancer conversation.

About the Author

Ali Ikhwan

Author

View All Posts

Post navigation

Previous: Navigating the "New Normal": Breast Cancer Canada Announces Comprehensive Survivorship Webinar Series for October 2026

Related Stories

navigating-the-new-normal-breast-cancer-canada-announces-comprehensive-survivorship-webinar-series-for-october-2026-3
  • Patient Advocacy and Support

Navigating the "New Normal": Breast Cancer Canada Announces Comprehensive Survivorship Webinar Series for October 2026

Iffa Jayyana October 19, 2026
navigating-the-complex-interplay-glp-1-medications-and-breast-cancer-risk-recurrence-and-treatment
  • Patient Advocacy and Support

Navigating the Complex Interplay: GLP-1 Medications and Breast Cancer Risk, Recurrence, and Treatment

Ammar Sabilarrohman October 19, 2026
global-illumination-the-2026-lightupmbc-campaign-and-the-urgent-push-for-metastatic-breast-cancer-research
  • Patient Advocacy and Support

Global Illumination: The 2026 #LightUpMBC Campaign and the Urgent Push for Metastatic Breast Cancer Research

Ammar Sabilarrohman October 19, 2026

Recent Posts

  • Global Landmarks to Glow in Teal, Green, and Pink for National Metastatic Breast Cancer Awareness Day
  • Navigating the "New Normal": Breast Cancer Canada Announces Comprehensive Survivorship Webinar Series for October 2026
  • Groundbreaking Oklahoma Research Uncovers How Aggressive Breast Cancer Hijacks Immune System to Fuel Growth
  • MacroGenics Initiates Landmark Phase I Trial for Novel Antibody-Drug Conjugate MGC030 in Advanced Solid Tumors
  • Navigating the Complex Interplay: GLP-1 Medications and Breast Cancer Risk, Recurrence, and Treatment

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

global-landmarks-to-glow-in-teal-green-and-pink-for-national-metastatic-breast-cancer-awareness-day
  • Patient Advocacy and Support

Global Landmarks to Glow in Teal, Green, and Pink for National Metastatic Breast Cancer Awareness Day

Ali Ikhwan October 19, 2026
navigating-the-new-normal-breast-cancer-canada-announces-comprehensive-survivorship-webinar-series-for-october-2026-3
  • Patient Advocacy and Support

Navigating the "New Normal": Breast Cancer Canada Announces Comprehensive Survivorship Webinar Series for October 2026

Iffa Jayyana October 19, 2026
groundbreaking-oklahoma-research-uncovers-how-aggressive-breast-cancer-hijacks-immune-system-to-fuel-growth-1
  • Medical Research and Clinical Trials

Groundbreaking Oklahoma Research Uncovers How Aggressive Breast Cancer Hijacks Immune System to Fuel Growth

Layla Zulfa October 19, 2026
macrogenics-initiates-landmark-phase-i-trial-for-novel-antibody-drug-conjugate-mgc030-in-advanced-solid-tumors
  • Medical Research and Clinical Trials

MacroGenics Initiates Landmark Phase I Trial for Novel Antibody-Drug Conjugate MGC030 in Advanced Solid Tumors

Suro Senen October 19, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.